SAB Biotherapeutics’ (SABS) Buy Rating Reiterated at Chardan Capital

Chardan Capital reiterated their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS) in a research note published on Monday morning, Benzinga reports. The brokerage currently has a $25.00 price target on the stock. Chardan Capital also issued estimates for SAB Biotherapeutics’ FY2024 earnings at ($3.68) EPS and FY2025 earnings at ($3.60) EPS.

A number of other research analysts also recently weighed in on the company. Brookline Capital Management began coverage on SAB Biotherapeutics in a research note on Friday, June 7th. They set a buy rating and a $8.00 price target on the stock. HC Wainwright restated a buy rating and set a $6.00 price objective on shares of SAB Biotherapeutics in a report on Tuesday, May 21st.

SAB Biotherapeutics Trading Up 1.8 %

SABS stock opened at $2.25 on Monday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.65 and a current ratio of 5.65. The company’s fifty day simple moving average is $2.84 and its 200 day simple moving average is $3.93. SAB Biotherapeutics has a 12-month low of $2.16 and a 12-month high of $10.50.

SAB Biotherapeutics (NASDAQ:SABS) last released its earnings results on Thursday, August 8th. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($1.13) by $0.34. SAB Biotherapeutics had a negative return on equity of 109.90% and a negative net margin of 1,531.26%. The business had revenue of $0.26 million during the quarter. As a group, research analysts predict that SAB Biotherapeutics will post -4.08 EPS for the current fiscal year.

Institutional Investors Weigh In On SAB Biotherapeutics

Several institutional investors have recently bought and sold shares of the stock. First PREMIER Bank bought a new position in SAB Biotherapeutics during the 2nd quarter valued at $60,000. Commodore Capital LP purchased a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at about $1,259,000. BVF Inc. IL purchased a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at about $6,310,000. Finally, RTW Investments LP bought a new position in shares of SAB Biotherapeutics during the fourth quarter valued at about $6,310,000. Institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.